Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
4.980
-0.120 (-2.35%)
At close: Mar 12, 2026, 4:00 PM EDT
5.03
+0.05 (1.02%)
After-hours: Mar 12, 2026, 4:20 PM EDT

Candel Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
---0.130.13
Gross Profit
---0.130.13
Selling, General & Admin
17.7714.0613.8914.0610.67
Research & Development
30.519.3124.5120.7915.18
Total Operating Expenses
48.2733.3738.3934.8525.85
Operating Income
-48.27-33.37-38.39-34.72-25.73
Interest Income
3.921.092.081.22-
Interest Expense
-2.12-2.09-2.6-1.71-
Other Non-Operating Income (Expense)
8.29-20.80.9716.42-10.4
Total Non-Operating Income (Expense)
10.08-21.810.4515.93-10.4
Pretax Income
-38.18-55.18-37.94-18.79-36.12
Net Income
-38.18-55.18-37.94-18.79-36.12
Net Income to Common
-38.18-55.18-37.94-18.79-36.12
Shares Outstanding (Basic)
5332292919
Shares Outstanding (Diluted)
5332292919
Shares Change (YoY)
67.19%9.47%0.39%52.72%62.49%
EPS (Basic)
-0.72-1.74-1.31-0.65-1.91
EPS (Diluted)
-0.72-1.74-1.31-0.65-1.91
Free Cash Flow
-38.9-27.04-34.7-32.72-24.05
Free Cash Flow Per Share
-0.73-0.85-1.20-1.14-1.27
Gross Margin
---100.00%100.00%
Operating Margin
----27777.60%-20580.80%
Profit Margin
----15035.20%-28899.20%
FCF Margin
----26172.80%-19242.40%
EBITDA
-47.42-32.38-37.43-33.94-25.49
EBITDA Margin
----27155.20%-20395.20%
EBIT
-48.27-33.37-38.39-34.72-25.73
EBIT Margin
----27777.60%-20580.80%
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q